22Aug 2022
iGlarLixi versus Basal Plus Rapid‐Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy: The SoliSimplify Real‐World Study

iGlarLixi versus Basal Plus Rapid‐Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy: The SoliSimplify Real‐World Study

For people with suboptimally controlled type 2 diabetes (T2D) on basal insulin (BI), guidelines recommend several treatment advancement options. This study compared the clinical effectiveness of once‐daily iGlarLixi versus a multiple‐injection BI + rapid acting insulin (RAI) regimen in adults with T2D advancing from BI therapy in real‐world clinical practice. In real‐world clinical practice, glycaemic outcomes 6 months after treatment advancement from BI are similar for people with T2D using iGlarLixi versus BI+RAI, with iGlarLixi leading to less weight gain.

  • #endo-diabetology

Like

Save

Share